MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63

MYCN amplification is a major biomarker of poor prognosis, occurring in 25-30% of neuroblastomas. MYCN plays contradictory roles in promoting cell growth and sensitizing cells to apoptosis. We have recently shown that p53 is a direct transcriptional target of MYCN in neuroblastoma and that p53-media...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamble, Laura D., Kees, Ursula R., Tweddle, Deborah A., Lunec, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191119/
https://www.ncbi.nlm.nih.gov/pubmed/21725357
http://dx.doi.org/10.1038/onc.2011.270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191119/
https://www.ncbi.nlm.nih.gov/pubmed/21725357
http://dx.doi.org/10.1038/onc.2011.270

Ejemplares similares